RecruitingNot ApplicableNCT06793904

Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS

Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS: A Prospective Cohort Study

Sponsor

Cairo University

Enrollment

122 participants

Start Date

Feb 1, 2025

Study Type

INTERVENTIONAL

Conditions

Polycystic Ovarian Syndrome (PCOS)

Summary

122 women diagnosed with PCOS seeking fertility in the fertility clinic at kasr Alainy hospital will be subjected to Homeostatic model assessment for insulin resistance 1 was calculated for all participants through the equation \[glucose (mmol/L) × insulin (µU/L)\]/22.5 while homeostatic model assessment for insulin resistance 2 was calculated by the HOMA2 calculator. All women will be subjected to induction of ovulation using the Aromatase inhibitor Letrozole 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days . Ultrasound follow up of follicular growth will be performed till dominant follicular size reaches 18-22 mm. FSH preparations will be introduced as needed.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study compares two different methods of measuring insulin resistance — HOMA1-IR and HOMA2-IR — in women with polycystic ovary syndrome (PCOS) who are being treated for infertility. The goal is to find out which method better predicts whether ovulation treatments will be successful. **You may be eligible if...** - You are a woman aged 18–35 with PCOS - You have been unable to conceive for 1–4 years **You may NOT be eligible if...** - Your infertility is caused by blocked tubes, uterine problems, or male factor issues - You have endometriosis, ovarian cysts, or diabetes - You have thyroid, hormonal, or immune disorders - You have chronic diseases or a history of poor ovarian response Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.